Investor Relations

Our mission is simple—help patients across the globe who suffer from pain and chronic conditions. We are doing this by harnessing the power of nVNS, innovation, and technology to develop a safe and clinically backed treatment. Bringing new treatments to market will help improve patients' treatment options and lives.

electroCore Expands Manufacturing Capabilities for gammaCore™

November 27, 2018 at 8:00 AM EST

BASKING RIDGE, N.J., Nov. 27, 2018 (GLOBE NEWSWIRE) -- electroCore, Inc. (“electroCore”) (Nasdaq:ECOR), a commercial-stage bioelectronic medicine company, today announced expansion into a new design and development facility to support increasing patient demand of its gammaCore™ non-invasive vagus nerve stimulator product.

“We are pleased to announce expansion into this new design, development and manufacturing facility which will ensure we can meet growing patient demand for gammaCore,” said Frank Amato, Chief Executive Officer of electroCore. “We look forward to enhancing and expanding our operational efficiency with modern capabilities to streamline prototyping and broader manufacturing and distribution resources.”

The 13,640-square-foot office and manufacturing facility is located at Forge Way Business Center in Rockaway, New Jersey. The Company plans to take occupancy in the first quarter of 2019.

electroCore, Inc. was founded in 2005 with the mission to help patients worldwide who suffer from pain and chronic conditions. The company’s first product, gammaCore, was cleared by the United States Food and Drug Administration for the acute treatment of pain associated with episodic cluster headache in April 2017 and for the acute treatment of pain associated with migraine in January 2018. The next generation of gammaCore, gammaCore Sapphire, was launched in August 2018 with improved design features for ease and comfort during patient use.

About electroCore, Inc.
electroCore, Inc. is a commercial-stage bioelectronic medicine company dedicated to improving patient outcomes through its platform non-invasive vagus nerve stimulation therapy initially focused on the treatment of multiple conditions in neurology and rheumatology. The Company’s initial targets are the acute treatment of migraine and episodic cluster headache.

For more information, visit www.electrocore.com.

Contacts
Investors:
Greg Chodaczek or Lynn Lewis
Gilmartin Group
investors@electrocore.com
(646) 924-1769

or

Media:
Alexandra Canale
GCI Health
(617) 921-9353
alexandra.canale@gcihealth.com

 

EC-Logo-2018_TM_CMYK.jpg